Last updated: September 24, 2026
Good Sense Lansoprazole is an over-the-counter, delayed-release lansoprazole product positioned as a private-label alternative to Prevacid 24HR and other proton-pump inhibitor products. Its commercial value depends less on active-ingredient exclusivity than on low-cost enteric protection, capsule stability, manufacturing yield, retailer access, and repeat-purchase economics.
The core excipient strategy is to protect lansoprazole from gastric acid while releasing it in the intestine. A practical formulation uses enteric-coated pellets or granules inside a hard capsule. Key excipient functions include acid-resistant polymer coating, buffering, plasticization, anti-tacking, moisture control, and protection from light and oxygen.
The main commercial opportunities are private-label retail expansion, lower-cost multi-count packages, e-commerce distribution, contract manufacturing, and differentiated packaging. Biosimilar risk is not relevant because lansoprazole is a small-molecule drug.
What is Good Sense Lansoprazole?
Good Sense Lansoprazole is an OTC 15 mg delayed-release capsule containing lansoprazole, a proton-pump inhibitor used for frequent heartburn. The product is intended for adults and children 18 years and older who experience heartburn two or more days per week. OTC labeling generally directs consumers to take one capsule daily for 14 consecutive days, with treatment courses limited under the Drug Facts label. [1]
| Product attribute |
Good Sense Lansoprazole |
| Active ingredient |
Lansoprazole |
| Strength |
15 mg |
| Dosage form |
Delayed-release capsule |
| Route |
Oral |
| Therapeutic category |
Proton-pump inhibitor |
| OTC indication |
Frequent heartburn |
| Standard regimen |
One capsule daily for 14 days |
| Typical retail positioning |
Store-brand alternative to Prevacid 24HR |
| Regulatory pathway |
OTC labeling under FDA requirements |
| Biosimilar exposure |
None |
| Primary formulation challenge |
Protecting lansoprazole from gastric degradation |
The product is generally sold through retail pharmacy, mass merchandise, grocery, club, and online channels under the Good Sense private-label brand. Product labeling and manufacturer information can vary by package configuration and market distribution. The marketed product label, rather than a general Good Sense brand description, controls the applicable inactive-ingredient disclosure.
What excipients protect Good Sense Lansoprazole?
The most important excipients are those used in the delayed-release pellet system. Public labeling for lansoprazole delayed-release capsules identifies excipient classes such as enteric polymers, buffering agents, capsule materials, coating aids, and pellet substrates. Exact excipient composition can differ among manufacturers and package presentations. [2]
| Excipient or excipient class |
Primary technical function |
Commercial relevance |
| Hypromellose |
Pellet or film-forming polymer |
Supports uniform coating and mechanical integrity |
| Methacrylic acid copolymer |
Enteric coating polymer |
Prevents release in the stomach and promotes intestinal release |
| Magnesium carbonate or another alkaline buffer |
Stabilizes lansoprazole microenvironment |
Limits acid-mediated degradation |
| Triethyl citrate |
Plasticizer |
Improves coating flexibility and reduces cracking |
| Polysorbate 80 |
Wetting or dispersion aid |
Supports coating uniformity |
| Talc |
Anti-tacking and coating aid |
Improves processing performance |
| Sugar spheres or inert pellet cores |
Drug-loading substrate |
Creates a uniform multiparticulate dosage form |
| Gelatin or hypromellose capsule shell |
Dosage-form enclosure |
Supports handling, identification, and consumer use |
| Titanium dioxide or approved colorants |
Opacity and product identification |
Helps distinguish product and protect light-sensitive contents |
Lansoprazole is acid-labile. A conventional immediate-release tablet would expose the active ingredient to gastric acid and reduce delivery to the absorption site. The formulation therefore normally combines drug-loaded pellets with an enteric coating and an alkaline microenvironment.
The formulation objective is not simply to delay disintegration. It is to maintain lansoprazole stability during manufacturing, storage, and gastric transit, then provide reproducible release in the upper intestine.
How does the enteric coating work?
Enteric polymers remain substantially intact at low gastric pH and dissolve at a higher intestinal pH. Methacrylic acid copolymers are widely used for this purpose. The coating must balance several properties:
- Resistance to gastric fluid.
- Rapid and reproducible release after gastric emptying.
- Mechanical durability during capsule filling and shipping.
- Low residual solvent and low moisture uptake.
- Acceptable dissolution performance over the product shelf life.
Coating weight gain is a major cost and quality variable. Excess coating increases material use, capsule fill volume, and manufacturing time. Insufficient coating can produce premature release or stability failures.
Why is buffering important?
Lansoprazole stability improves when the drug is protected from an acidic microenvironment. An alkaline buffer can be incorporated into the pellet core, the drug layer, or an intermediate coating. The buffer must remain compatible with the drug, polymer system, manufacturing process, and dissolution profile.
Buffer selection affects:
- Chemical stability.
- Pellet porosity.
- Drug-layer uniformity.
- Release onset.
- Moisture sensitivity.
- Compatibility with capsule-shell materials.
A formulation with strong acid protection but excessive alkalinity can create processing or dissolution problems. The commercial target is a narrow formulation window that preserves potency without increasing capsule size or manufacturing complexity.
What formulation patents protect lansoprazole products?
The original lansoprazole composition and formulation patent estate is largely historical. The principal commercial barriers for an OTC private-label product are regulatory compliance, manufacturing capability, supply reliability, and retailer economics rather than broad exclusivity over lansoprazole itself.
The original Prevacid product was developed by Takeda Pharmaceuticals. Lansoprazole patents associated with the original product and certain formulations expired years ago, allowing generic and private-label competition. FDA-approved generic delayed-release capsules have been marketed by multiple manufacturers. [3]
| Protection category |
Current commercial significance |
| Active-ingredient patent |
Generally expired |
| Original delayed-release formulation patents |
Historical or expired for core commercial products |
| OTC regulatory exclusivity |
No meaningful current exclusivity barrier for established lansoprazole products |
| Manufacturing know-how |
Moderate importance |
| Pellet-coating process |
Potentially valuable as trade secret or process IP |
| Packaging and moisture protection |
Commercially important but usually not a blocking patent |
| Trademark and private-label rights |
Relevant to brand and retailer control |
| New formulation patents |
Possible if tied to a genuinely differentiated delivery system |
A new patent position could arise from a specific pellet architecture, coating sequence, stability-enhancing excipient combination, capsule technology, or alternative dosage form. Broad claims covering lansoprazole plus ordinary enteric excipients would face substantial validity and obviousness pressure because delayed-release lansoprazole technology is established.
What is the FDA regulatory status of Good Sense Lansoprazole?
The product is regulated as an OTC drug. FDA OTC requirements govern active-ingredient labeling, indications, warnings, directions, and conditions of use. Lansoprazole 15 mg products are marketed for short-term treatment of frequent heartburn under the FDA OTC framework. [1,4]
The principal regulatory requirements include:
- Correct active-ingredient declaration.
- Valid delayed-release performance.
- Stability through the labeled expiration date.
- Compliance with current good manufacturing practices.
- Appropriate Drug Facts labeling.
- Uniformity of dosage units.
- Dissolution and release testing.
- Control of impurities and degradation products.
- Correct packaging and tamper-evident presentation where applicable.
The product does not depend on biologic comparability or biosimilar approval. It is a chemically synthesized small molecule. A competing manufacturer generally competes through an OTC monograph-compliant product, an approved abbreviated pathway where applicable, or a private-label arrangement supported by the relevant regulatory filing and manufacturing controls.
What is the Orange Book status of Good Sense Lansoprazole?
Good Sense Lansoprazole is not commercially dependent on an active innovator patent barrier comparable to a newly launched prescription product. The Orange Book is primarily relevant to approved prescription drug products and patent certifications. OTC private-label products are generally evaluated through OTC regulatory requirements rather than relying on a current Orange Book patent term to protect the product.
For business purposes, the key conclusion is that a Paragraph IV challenge is not the central entry issue for Good Sense Lansoprazole. The molecule and delayed-release dosage form are already subject to broad generic competition. A new prescription or reformulated lansoprazole product could create a different Orange Book and patent-certification analysis, but the standard Good Sense OTC product does not have a meaningful exclusivity moat based on core lansoprazole patents.
When does lansoprazole lose exclusivity?
Core lansoprazole exclusivity was lost well before the current private-label market developed. Prevacid’s original market protection has expired, and generic delayed-release lansoprazole products are widely available.
| Exclusivity element |
Status |
| New chemical entity exclusivity |
Expired |
| Original innovator patent protection |
Expired or commercially non-blocking |
| Generic delayed-release competition |
Established |
| OTC private-label entry |
Available subject to regulatory compliance |
| Current exclusivity for Good Sense brand |
Brand-specific, not molecule-specific |
| Consumer switching barriers |
Low to moderate |
Good Sense competes through price, shelf placement, retailer trust, package count, and supply continuity. The brand does not need to own the active ingredient or a blocking formulation patent to capture demand.
How strong is the Good Sense Lansoprazole patent estate?
The patent estate is likely weak as a blocking estate and stronger as a formulation and operational platform.
Blocking patent strength
The estate has limited ability to prevent competitors from selling lansoprazole delayed-release products because:
- Lansoprazole is an established generic active ingredient.
- Delayed-release pellet technology is mature.
- Enteric polymers and alkaline buffers are conventional formulation tools.
- Multiple suppliers can manufacture comparable products.
- OTC consumers can substitute among store brands, generic labels, and national brands.
Process and trade-secret strength
Manufacturing know-how can still create an operational advantage. Important areas include:
- Drug-layer application onto inert pellets.
- Control of pellet size distribution.
- Uniform enteric-coat application.
- Prevention of agglomeration.
- Low-moisture processing.
- Capsule-fill weight control.
- Stability under warehouse and retail conditions.
- Scale-up from pilot coating to commercial batches.
These assets may not prevent competition, but they can reduce batch failures, improve yield, and lower cost per sellable capsule.
What commercial opportunities exist for Good Sense Lansoprazole?
Private-label retail expansion
The clearest opportunity is broader retailer penetration. Lansoprazole is suited to private-label programs because the active ingredient is established, consumer demand is predictable, and packaging can be adapted to retailer specifications.
Potential channels include:
- Regional pharmacy chains.
- Grocery pharmacies.
- Mass merchants.
- Club stores.
- E-commerce marketplaces.
- Employer and health-plan purchasing programs.
- International retailers requiring localized OTC labeling.
Retailers can offer 14-count, 28-count, 42-count, and larger packages. The 14-count format maps to the standard treatment course. Larger packages improve unit economics but may create greater inventory exposure and lower purchase frequency.
Price-tier architecture
A manufacturer or brand owner can create several price tiers:
| Tier |
Product strategy |
Target customer |
| Value |
Basic 15 mg delayed-release capsule |
Price-sensitive OTC shopper |
| Standard |
Established store-brand package |
Mainstream pharmacy customer |
| Premium private label |
Improved packaging, larger count, stronger shelf presentation |
Convenience-oriented consumer |
| Club or e-commerce |
High-count pack with low unit price |
Repeat users and households |
The greatest margin opportunity often comes from packaging and channel mix rather than changing the active formulation.
Manufacturing and supply agreements
Contract manufacturing agreements can produce revenue through:
- Finished-dose manufacturing.
- Pellet coating.
- Capsule filling.
- Packaging and serialization.
- Retailer-specific labeling.
- Stability and annual product testing.
- Geographic supply exclusivity.
A manufacturer with validated lansoprazole pellet technology can supply several private labels from one core formulation. The commercial risk is customer concentration. Losing one major retailer can create excess inventory, packaging obsolescence, and plant underutilization.
Formulation extensions
Potential differentiated products include:
- Smaller capsules.
- Color-free capsules.
- Vegetarian capsule shells.
- Improved moisture-barrier packaging.
- Pediatric or age-specific presentations, subject to regulatory support.
- Alternative multiparticulate dosage forms.
- Combination products with other heartburn ingredients, subject to FDA requirements.
- Unit-dose blister packaging for travel and adherence.
The strongest near-term opportunities are packaging and channel extensions. New clinical claims or major delivery innovations would require more substantial regulatory and development investment.
What manufacturing and IP barriers affect market entry?
Entry barriers are moderate operationally and low at the molecule level.
Technical barriers
A new entrant must establish:
- Reproducible drug loading.
- Uniform enteric coating.
- Reliable dissolution across batches.
- Adequate stability.
- Low degradation-product formation.
- Capsule compatibility.
- Consistent fill weight and content uniformity.
Supply-chain barriers
Commercial supply depends on:
- Lansoprazole API availability.
- Enteric-polymer supply.
- Inert pellet availability.
- Capsule-shell supply.
- Coating equipment capacity.
- Packaging-component lead times.
- Retailer forecasting accuracy.
IP barriers
The principal IP risks are more likely to involve:
- A specific novel pellet configuration.
- A proprietary coating process.
- A new combination product.
- A branded packaging or dispensing system.
- Trademark conflicts.
- Contractual exclusivity with a retailer.
Routine use of standard excipients is unlikely to create a durable patent barrier. A competitor should still conduct a freedom-to-operate review for any new formulation, coating sequence, combination product, or jurisdiction-specific launch.
Which companies challenge Good Sense Lansoprazole?
The competitive field includes national brands, generic manufacturers, private-label suppliers, and retailers.
| Competitor group |
Examples |
| National brand |
Prevacid 24HR |
| Generic manufacturers |
Multiple FDA-authorized lansoprazole suppliers |
| Retail private labels |
Pharmacy, grocery, mass-retail, and club-store brands |
| Alternative PPIs |
Omeprazole, esomeprazole, pantoprazole products |
| Alternative acid reducers |
Famotidine and related H2-receptor antagonists |
Competition is based on retail price, product availability, consumer recognition, package count, and perceived effectiveness. A competitor does not need a superior excipient system if it can offer acceptable dissolution, reliable supply, and lower total cost.
What is the revenue exposure for a Good Sense Lansoprazole supplier?
Revenue exposure depends on retailer concentration and product substitution. The product has a relatively low clinical switching barrier because consumers can move among lansoprazole brands or use other OTC acid-reduction products.
Key commercial risks include:
- Retailer delisting.
- Price compression.
- API or enteric-polymer shortages.
- Product recalls caused by dissolution or stability failures.
- Consumer migration to omeprazole or esomeprazole.
- E-commerce price competition.
- Excess inventory after package redesign.
- Margin erosion from retailer bidding.
A supplier can reduce exposure by supporting multiple private-label customers, using common manufacturing platforms, and maintaining flexible packaging operations.
What generic launch scenarios exist for lansoprazole?
Low-price generic launch
A new entrant can launch a conventional 15 mg delayed-release capsule with minimal differentiation. This approach requires strong cost control and access to retail or wholesale distribution.
Retailer-exclusive launch
A manufacturer can offer a retailer an exclusive store-brand product or package count. The agreement may improve shelf access but increase dependence on one customer.
Premium packaging launch
A supplier can differentiate through blister packaging, moisture protection, senior-friendly opening systems, or travel formats. These changes may improve retail presentation without altering the active formulation.
Formulation innovation launch
A new pellet or capsule system could support patent filings, but the development burden and regulatory cost would be higher. The product would need a clear consumer or manufacturing advantage to justify the investment.
What litigation and settlement risks affect the product?
There is no apparent current litigation theme that gives Good Sense Lansoprazole a material exclusivity advantage. The relevant risks are ordinary for an established OTC generic product:
- Patent disputes involving a genuinely new formulation.
- Trademark disputes involving private-label naming.
- Product-liability claims.
- FDA manufacturing or labeling enforcement.
- Contract disputes with retailers.
- Supplier quality claims.
- Recall-related indemnification disputes.
Paragraph IV litigation is more relevant to a newly approved prescription formulation or a new patented delivery system than to a conventional OTC lansoprazole capsule. Settlement agreements would matter if a new branded formulation sought to delay or control generic entry, but they do not appear central to the established Good Sense product.
How does Good Sense Lansoprazole compare with competing PPIs?
| Attribute |
Lansoprazole |
Omeprazole |
Esomeprazole |
| OTC availability |
Established |
Established |
Established |
| Typical OTC strength |
15 mg |
20 mg |
20 mg |
| Dosage form |
Usually delayed-release capsule |
Capsule or tablet |
Capsule or tablet |
| Formulation sensitivity |
High acid sensitivity |
High acid sensitivity |
High acid sensitivity |
| Enteric protection |
Required |
Required |
Required |
| Private-label competition |
High |
Very high |
High |
| Differentiation opportunity |
Moderate |
Limited by intense competition |
Moderate |
| Main commercial variable |
Price and supply |
Price and brand recognition |
Brand and perceived potency |
Good Sense Lansoprazole has a viable commercial position, but its competitive advantage is unlikely to come from the active ingredient. Its strongest levers are retailer relationships, cost-efficient pellet coating, stable supply, compliant labeling, package architecture, and disciplined inventory management.
Key Takeaways
- Good Sense Lansoprazole is an OTC 15 mg delayed-release lansoprazole capsule.
- The formulation depends on enteric protection and an alkaline microenvironment.
- Hypromellose, methacrylic acid copolymers, buffering agents, triethyl citrate, talc, polysorbate 80, pellet substrates, and capsule-shell materials perform distinct technical functions.
- Core lansoprazole exclusivity has expired, and the product faces established generic and private-label competition.
- Paragraph IV litigation and biosimilar risk are not central to the current product.
- Manufacturing know-how, coating yield, stability control, and supply reliability are more commercially important than active-ingredient patents.
- The strongest opportunities are private-label expansion, retailer-exclusive packages, e-commerce packs, contract manufacturing, and moisture-protective packaging.
- New formulation patents would need a specific technical advance because conventional delayed-release lansoprazole systems are mature.
- Revenue risk is concentrated in retailer dependence, price compression, quality failures, and substitution by other proton-pump inhibitors.
FAQs
Is Good Sense Lansoprazole the same as Prevacid 24HR?
It contains the same active ingredient, lansoprazole, at the common OTC 15 mg strength. Inactive ingredients, capsule design, packaging, manufacturer, and retail price can differ.
Can lansoprazole be sold without an enteric coating?
A conventional oral lansoprazole product generally requires acid protection because the active ingredient is acid-labile. An alternative dosage form would need validated stability and release performance.
Are lansoprazole excipients patentable?
An individual excipient is generally not patentable merely because it is used in the product. A novel excipient combination, coating architecture, manufacturing sequence, or stability result may support patent claims if it satisfies patentability requirements.
What is the most valuable commercial improvement for Good Sense Lansoprazole?
The highest-probability improvements are lower coating cost, better moisture protection, larger-count packages, retailer-exclusive formats, and packaging designed for e-commerce and travel use.
Does Good Sense Lansoprazole have biosimilar competition?
No. Lansoprazole is a chemically synthesized small molecule. Competition comes from generic and private-label drug products, not biosimilars.
References
- U.S. Food and Drug Administration. (n.d.). Lansoprazole 15 mg delayed-release capsule labeling and OTC drug facts requirements. FDA.
- National Library of Medicine. (n.d.). DailyMed: Lansoprazole capsule, delayed release. DailyMed.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.
- U.S. Food and Drug Administration. (n.d.). Over-the-counter drug monograph for proton-pump inhibitor products. FDA.
